. Author manuscript; available in PMC: 2011 Aug 1.

Published in final edited form as: Psychopharmacology (Berl). 2010 May 19;211(2):141–148. doi: 10.1007/s00213-010-1875-y

Table 3.

Performance on selected psychomotor and cognitive tasks (mean±SEM) as a function of placebo, naltrexone dose, and marijuana strength

		Naltrexone dose

Variable	MJ strength	0 mg	12 mg	25 mg	50 mg	100 mg
DAT: average speed (cm/s)	Inactive	7.3 (0.2)	6.6 (0.2)^*	6.9 (0.2)^*	6.7 (0.2)^*	7.0 (0.2)^*
	Active	7.0 (0.2)	7.0 (0.2)	7.1 (0.2)	6.9 (0.2)	6.9 (0.2)
DSST:Total attempts	Inactive	86.2 (1.8)	86.7 (1.7)	83.4 (1.7)	83.6 (1.8)	82.1 (1.6)^*
	Active	86.1 (1.7)	84.7 (1.6)	83.5 (1.6)	82.1 (1.4)^*	83.0 (1.7)^*
DRT: delayed recognition (% correct)	Inactive	66.7 (5.1)	57.5 (5.3)	49.4 (5.4)^*	60.9 (5.3)	63.2 (5.2)
	Active	66.7 (5.1)	57.5 (5.3)	57.5 (5.3)	59.8 (5.3)^*	66.7 (5.1)

Data are presented as average values (±SEM) across post-smoking time points (30, 75, and 180 min after smoking). Significant differences between active and placebo naltrexone are indicated (*p≤0.01)